Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MediClin AGXTER:MED +0.48%78 3-Year ROIIC % is -22.02 as of Dec. 2025. GuruFocus rates XTER:MED with a GF Score™ of 78/100 and a GF Value™ of €3.04 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 618 Healthcare Providers & Services companies, MediClin AG ranks worse than 77.18% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
MediClin AG's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was -22.02%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for MediClin AG's 3-Year ROIIC % or its related term are showing as below:
XTER:MED's 3-Year ROIIC % is ranked worse than 77.18% of 618
companies
in the Healthcare Providers & Services industry
Industry Median: 3.37
vs XTER:MED: -22.02
MediClin AG (XTER:MED) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
MediClin AG 3-Year ROIIC % Related Terms
MediClin AG 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for MediClin AG's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XTER:MED vs HCA, THC, DVA: 3-Year ROIIC % Comparison
For the Medical Care Facilities subindustry, MediClin AG's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MediClin AG 3-Year ROIIC % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, MediClin AG's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where MediClin AG's 3-Year ROIIC % falls into.
MediClin AG's 3-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( 38.63475 (Dec. 2025) - 18.2636052 (Dec. 2022) )
/
( 688.093 (Dec. 2025) - 780.624 (Dec. 2022) )
=
20.3711448
/
-92.531
=
-22.02%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
MediClin AG (XTER:MED) has a 3-Year ROIIC % of -22.02 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on MediClin AG and its competitors. According to the industry distribution chart, MediClin AG ranks #477 out of 618 companies in the Healthcare Providers & Services industry, placing it in the top 77.2%.
Is MediClin AG's 3-Year ROIIC % too high?
MediClin AG's current 3-Year ROIIC % is -22.02. Based on the distribution chart, MediClin AG ranks #477 out of 618 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, MediClin AG has a GF Score™ of 78/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does MediClin AG's 3-Year ROIIC % compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, MediClin AG ranks #477 out of 618 companies for 3-Year ROIIC %. This places MediClin AG in the lower half of its industry. The industry median 3-Year ROIIC % is 3.37. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Healthcare Providers & Services company?
The median 3-Year ROIIC % among Healthcare Providers & Services companies is 3.37, based on 618 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on MediClin AG and its competitors. For the Healthcare Providers & Services industry, the median 3-Year ROIIC % is 3.37 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MediClin AG's current 3-Year ROIIC % is -22.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MediClin AG stock overvalued right now?
Based on GuruFocus' analysis, MediClin AG (XTER:MED) is currently considered Significantly Overvalued. The stock's GF Value™ is €3.04, compared to a current price of €4.16 — trading 36.8% above its estimated fair value. The current 3-Year ROIIC % is -22.02. MediClin AG's overall GF Score™ is 78/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For MediClin AG (XTER:MED), the current 3-Year ROIIC % is -22.02 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MediClin AG (XTER:MED) Overvalued in 2026?
Based on GuruFocus' analysis, MediClin AG stock appears to be overvalued.
The current stock price of €4.16 is trading 36.8% above its estimated GF Value™ of €3.04.
GuruFocus considers MediClin AG to be Significantly Overvalued.
Key valuation signals for XTER:MED:
3-Year ROIIC %: -22.02
GF Value™: €3.04 vs. price of €4.16 (36.8% above fair value)
No single metric tells the full story. See the XTER:MED stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MediClin AG operates hospitals and other medical care centers. The company's reportable operating segments are the Post-acute, Acute, Nursing care, and Service segments. A majority of its revenue is generated from the Post-acute segment, which offers services in the fields of follow-up rehabilitation treatment and curative treatment. Some of the post-acute hospitals also offer services in acute neurology and acute psychosomatics. The Acute segment encompasses medical offerings with a focus on neurology and neurological early rehabilitation as well as psychosomatic medicine, psychiatry, orthopaedics, and internal medicine. The Nursing care segment offers full-time and part-time nursing care as well as daycare, and the Service segment consists of the central services.
78GF Score
Get the complete analysis for XTER:MED
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XTER:MED has been successfully added to your 
